Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

US Congressional Hearing Will Look At Mature Brands

Executive Summary

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.

You may also be interested in...



US Industry Welcomes Nomination Of Califf To FDA Helm For A Second Time

The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.

Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing

Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.

Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing

Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel